Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001

BIOXYTRAN, INC

100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
No viral rebounds observed during the 14-day post-treatment observation period.
16 of 38 subjects had non-detection by Day 5; 1 of 38 by Day 3.
Phase 2 dose-optimization trial: randomized, double-blind, 38 subjects completed.
Company plans regulatory discussions for late-stage development and additional viral indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.